Large randomized trials have confirmed the cardiorenal benefits from sodium-glucose transporter 2 (SGLT2) inhibitors for patients with type 2 diabetes (T2D), for patients with chronic heart failure and reduced ejection fraction (HFrEF), and for patients with chronic kidney disease (CKD). However, whether these cardiorenal benefits vary in different chronic diseases or vary with specific SGLT2 inhibitors remains unclear. Thus, we conducted this meta-analysis based on cardiovascular and renal outcome trials of SGLT2 inhibitors, and aimed at exploring the differences in the cardiorenal benefits from four SGLT2 inhibitors in three chronic diseases.
